SCHEMBL1635905

SCHEMBL1635905

CNC(=O)[C@@H]1CC12CCCCC2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44
GAA P10253 2/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPK1 P28482 2/20 0.38
CYP2C9 P11712 1/20 0.38
TSHR P16473 1/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 1/20 0.35
HRH3 Q9Y5N1 2/20 0.33
KCNH2 Q12809 1/20 0.33
MAPT P10636 1/20 0.33
GBA1 P04062 1/20 0.33
MGAT2 Q10469 1/20 0.32
DGAT2 Q96PD7 1/20 0.32
NPSR1 Q6W5P4 1/20 0.31
CHRNB2 P17787 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1634885 1.00 LMNA (0.44) LMNAHPGDGAAALDH1A1MAPK1
SCHEMBL13411548 0.94 LMNA (0.49) LMNAHPGDGAAALDH1A1MAPK1
SCHEMBL19566786 0.94 LMNA (0.49) LMNAHPGDGAAALDH1A1MAPK1
SCHEMBL19539238 0.89
SCHEMBL26345308 0.82 LMNA (0.36) LMNAHPGDGAAALDH1A1NPC1
SCHEMBL1635847 0.77 LMNA (0.43) LMNAHPGDGAAALDH1A1MAPK1
SCHEMBL1635537 0.77 LMNA (0.43) LMNAHPGDGAAALDH1A1MAPK1
SCHEMBL1634491 0.77 LMNA (0.43) LMNAHPGDGAAALDH1A1MAPK1
SCHEMBL1634465 0.77 LMNA (0.43) LMNAHPGDGAAALDH1A1MAPK1
SCHEMBL24124140 0.73 LMNA (0.30) LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932245-B2 Spirocyclopropyl amides and acids and their therapeutic applications ABBOTT LABORATORIES (US) 2011-04-26 US disclosed
EP-1558230-B1 SPIROCYCLOPROPYL AMIDES AND ACIDS AND THEIR THERAPEUTIC APPLICATIONS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20040204396-A1 Spirocyclopropyl amides and acids and their therapeutic applications ABBVIE INC. 2004-10-14 US disclosed
US-20040077616-A1 Spirocyclopropyl amides and acids and their therapeutic applications ABBOTT LABORATORIES 2004-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077616-A1 Spirocyclopropyl amides and acids and their therapeutic applications SCN1A, SCN1B, SCN10A LMNA 1139/4885HPGD 593/4885GAA 1897/4885
US-20040204396-A1 Spirocyclopropyl amides and acids and their therapeutic applications SCN1A, SCN1B, SCN10A LMNA 1139/4885HPGD 593/4885GAA 1897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.